198 related articles for article (PubMed ID: 23494387)
1. Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer.
Black CC; Turk MJ; Dragnev K; Rigas JR
Lung; 2013 Jun; 191(3):265-70. PubMed ID: 23494387
[TBL] [Abstract][Full Text] [Related]
2. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma.
Schneider T; Kimpfler S; Warth A; Schnabel PA; Dienemann H; Schadendorf D; Hoffmann H; Umansky V
J Thorac Oncol; 2011 Mar; 6(3):432-8. PubMed ID: 21258248
[TBL] [Abstract][Full Text] [Related]
3. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
4. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer.
Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y
Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
Shimizu K; Nakata M; Hirami Y; Yukawa T; Maeda A; Tanemoto K
J Thorac Oncol; 2010 May; 5(5):585-90. PubMed ID: 20234320
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.
Ganesan AP; Johansson M; Ruffell B; Yagui-Beltrán A; Lau J; Jablons DM; Coussens LM
J Immunol; 2013 Aug; 191(4):2009-17. PubMed ID: 23851682
[TBL] [Abstract][Full Text] [Related]
7. Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.
O'Callaghan DS; Rexhepaj E; Gately K; Coate L; Delaney D; O'Donnell DM; Kay E; O'Connell F; Gallagher WM; O'Byrne KJ
Eur Respir J; 2015 Dec; 46(6):1762-72. PubMed ID: 26541534
[TBL] [Abstract][Full Text] [Related]
8. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.
Tao H; Mimura Y; Aoe K; Kobayashi S; Yamamoto H; Matsuda E; Okabe K; Matsumoto T; Sugi K; Ueoka H
Lung Cancer; 2012 Jan; 75(1):95-101. PubMed ID: 21719142
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of FoxP3+ T regulatory cells in the tumor microenvironment of human colorectal adenomas.
Hua W; Yuan A; Zheng W; Li C; Cui J; Pang Z; Zhang L; Li Z; Goll R; Cui G
Pathol Res Pract; 2016 Feb; 212(2):106-12. PubMed ID: 26724144
[TBL] [Abstract][Full Text] [Related]
11. Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area.
Heeren AM; de Boer E; Bleeker MC; Musters RJ; Buist MR; Kenter GG; de Gruijl TD; Jordanova ES
Oncotarget; 2015 Oct; 6(32):32484-93. PubMed ID: 26431490
[TBL] [Abstract][Full Text] [Related]
12. Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinoma.
Zhao L; Yang J; Wang HP; Liu RY
Med Oncol; 2013 Mar; 30(1):461. PubMed ID: 23335103
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of expanded Foxp3⁺ Helios⁻ regulatory T cells in patients with non-small cell lung cancer.
Muto S; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Suzuki H; Gotoh M
Int J Oncol; 2015 Dec; 47(6):2082-90. PubMed ID: 26460798
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.
Suzuki K; Kadota K; Sima CS; Nitadori J; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
J Clin Oncol; 2013 Feb; 31(4):490-8. PubMed ID: 23269987
[TBL] [Abstract][Full Text] [Related]
16. Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8 + and regulatory FOXP3 + cells tumor-associated infiltrate and other prognostic factors.
Glajcar A; Łazarczyk A; Tyrak KE; Hodorowicz-Zaniewska D; Streb J; Okoń K; Szpor J
Virchows Arch; 2021 Nov; 479(5):871-882. PubMed ID: 34117905
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
Tian Y; Zhai X; Yan W; Zhu H; Yu J
Cancer Med; 2021 Jan; 10(1):3-14. PubMed ID: 33230935
[TBL] [Abstract][Full Text] [Related]
18. In situ analysis of CCR8
Hayashi Y; Ueyama A; Funaki S; Jinushi K; Higuchi N; Morihara H; Hirata M; Nagira Y; Saito T; Kawashima A; Iwahori K; Shintani Y; Wada H
BMC Cancer; 2024 May; 24(1):627. PubMed ID: 38783281
[TBL] [Abstract][Full Text] [Related]
19. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive bioinformatics analysis of FOXP3 in nonsmall cell lung cancer.
Zhu J; Li Z; Chen J; Li W; Wang H; Jiang T; Ma Y
Medicine (Baltimore); 2022 Dec; 101(50):e32102. PubMed ID: 36550816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
